Inicio › Cáncer de próstata › Texas
Ensayos clínicos de Cáncer de próstata en Texas
113 estudios sobre Cáncer de próstata buscan participantes en Texas.
Ciudades en Texas
- Houston73 estudios
- Dallas39 estudios
- San Antonio27 estudios
- Austin14 estudios
- Fort Worth10 estudios
- The Woodlands7 estudios
- Richardson6 estudios
- League City4 estudios
- Sugar Land4 estudios
- Arlington3 estudios
- Irving3 estudios
Texto oficial del estudio (inglés)
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- Parkland Memorial Hospital, Dallas
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- y 3 más
ReclutandoFase 3
Edades de 18 en adelante · Hombres · Actualizado el 13 nov 2026 · NCT04423211Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- UT MD Anderson Cancer Center, Houston
ReclutandoFase 2
Edades de 18 en adelante · Hombres · Actualizado el 12 nov 2026 · NCT05691465Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
- University of Texas MD Anderson Cancer Center, Houston
ReclutandoFase 1
Edades de 18 en adelante · Hombres · Actualizado el 12 nov 2026 · NCT04221542Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
- y 1 más
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT03866382An Evidence-Based Focal Cryotherapy Protocol for Focal Ablation of Intermediate Risk Prostate Cancer
- MD Anderson Cancer Center, Houston
ReclutandoFase 2
Edades de 18 en adelante · Hombres · Actualizado el 12 nov 2026 · NCT05454488Sacral Neuromodulation for Male Overactive Bladder (MOAB)
- Urology Partners of North Texas (UPNT), Arlington
Reclutando
Edades de 18 en adelante · Hombres · Actualizado el 12 nov 2026 · NCT06511141Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
- The University of Texas, MD Anderson Cancer Center - West Houston, Houston
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT04557449WATER IV PCa (AS Sub-study)
- Midtown Urology, Austin
- Urology Austin, Austin
- Urology Clinics of North Texas, Dallas
Reclutando
Edades de 45 en adelante · Hombres · Actualizado el 6 nov 2026 · NCT07650448Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence
- Urology Austin, Austin
ReclutandoFase 4
Edades de 18 en adelante · Hombres · Actualizado el 5 nov 2026 · NCT07569926A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- University of Texas MD Anderson Cancer Center, Houston
- South Texas Accelerated Research Therapeutics (START), San Antonio
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06465069Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- The Don and Sybil Harrington Cancer Center, Amarillo
- UT MD Anderson Cancer Center, Houston
- Audie L Murphy VA Hospital, San Antonio
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Edades de 40 a 75 · Todos los sexos · Actualizado el 4 nov 2026 · NCT05334069A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Texas Oncology - DFW (Sammons CC), Dallas
- MD Anderson Cancer Center, Houston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT07114601Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
- y 1 más
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT06632977A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
- Urology Clinics Of North Texas, Dallas
- Urology Partners of North Texas (UPNT), Fort Worth
- Houston Metro Urology (HMU), Houston
ReclutandoFase 3
Edades de 18 en adelante · Hombres · Actualizado el 3 nov 2026 · NCT07723248NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial
- M D Anderson Cancer Center, Houston
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT06066437A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
- MD Anderson Cancer Center, Houston
- South Texas Accelerated Research Therapeutics, LLC (START), San Antonio
ReclutandoFase 1
Edades de 18 en adelante · Hombres · Actualizado el 3 nov 2026 · NCT06095089Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
- Covenant Medical Center-Lakeside, Lubbock
ReclutandoFase 3
Edades de 18 en adelante · Hombres · Actualizado el 3 nov 2026 · NCT07200830Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
- y 1 más
ReclutandoFase 3
Edades de 18 en adelante · Hombres · Actualizado el 3 nov 2026 · NCT06931340Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
- NEXT Oncology, Austin
- MD Anderson Cancer Center, Houston
ReclutandoFase 1/2
Edades de 18 en adelante · Hombres · Actualizado el 3 nov 2026 · NCT06800313A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate Cancer
- Renovatio Clinical 1, El Paso
- Renovatio Clinical, The Woodlands
ReclutandoFase 3
Edades de 18 en adelante · Hombres · Actualizado el 3 nov 2026 · NCT07906717A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
- SCRI Oncology Partners, Nashville
ReclutandoFase 1
Edades de 18 en adelante · Hombres · Actualizado el 3 nov 2026 · NCT05800665A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors
- MD Anderson Cancer Center, Houston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 nov 2026 · NCT07887971Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
- M D Anderson Cancer Center, Houston
ReclutandoFase 2
Edades de 18 en adelante · Hombres · Actualizado el 2 nov 2026 · NCT05873192A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- Parkland Health & Hospital System ( Site 0069), Dallas
- UT Southwestern Medical Center ( Site 0039), Dallas
- University of Texas-MD Anderson Cancer Center ( Site 0055), Houston
ReclutandoFase 3
Edades de 18 en adelante · Hombres · Actualizado el 30 oct 2026 · NCT06925737Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- Mary Crowley Cancer Research, Dallas
- University of Texas Southwestern Medical Center, Dallas
- Houston Methodist Hospital, Houston
ReclutandoFase 1
Edades de 18 a 100 · Hombres · Actualizado el 29 oct 2026 · NCT05519449Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
- START, San Antonio
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 oct 2026 · NCT07288359Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
- MD Anderson Cancer Center, Houston
ReclutandoFase 1
Edades de 18 en adelante · Hombres · Actualizado el 27 oct 2026 · NCT05997615A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
- Michael E. DeBakey VA Medical Center, Houston, TX, Houston
ReclutandoFase 2
Edades de 18 en adelante · Hombres · Actualizado el 26 oct 2026 · NCT05593497A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 26 oct 2026 · NCT06172478A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
- Mary Crowley Cancer Research, Dallas
ReclutandoFase 1
Edades de 18 en adelante · Hombres · Actualizado el 23 oct 2026 · NCT07570979Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- UT MD Anderson - The Woodlands, Conroe
- Brooke Army Medical Center, Fort Sam Houston
- UT MD Anderson Cancer Center, Houston
- y 3 más
ReclutandoFase 3
Edades de 18 en adelante · Hombres · Actualizado el 23 oct 2026 · NCT05946213Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
- Research Site, Houston
ReclutandoFase 1/2
Edades de 18 a 130 · Hombres · Actualizado el 22 oct 2026 · NCT07181161A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Research Site 135, Austin
- Research Site 120, Dallas
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 21 oct 2026 · NCT05914116A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
- USA Clinical Trials, San Antonio
ReclutandoFase 1
Edades de 18 en adelante · Hombres · Actualizado el 20 oct 2026 · NCT07103018A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- Texas Oncology - Central/South Texas ( Site 8003), Austin
- Texas Oncology - DFW ( Site 8001), Dallas
- Texas Oncology - Gulf Coast ( Site 8002), Houston
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 20 oct 2026 · NCT06136650Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- START San Antonio, San Antonio
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 20 oct 2026 · NCT06582017A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- The Center for Cancer and Blood Disorders, Arlington
- University of Texas Southwestern Medical Center, Dallas
- Renovatio Clinical, Houston
- y 2 más
ReclutandoFase 3
Edades de 18 en adelante · Hombres · Actualizado el 20 oct 2026 · NCT07213674AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
- Research Site, Houston
ReclutandoFase 3
Edades de 18 en adelante · Hombres · Actualizado el 19 oct 2026 · NCT07611110Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- MD Anderson Cancer Center, Houston
- NEXT Oncology, San Antonio
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 15 oct 2026 · NCT06239194Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
- Research Site, Austin
- Research Site, Dallas
- Research Site, Fort Worth
- y 2 más
ReclutandoFase 3
Edades de 18 en adelante · Hombres · Actualizado el 15 oct 2026 · NCT07711002De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.